Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.
J. Med. Chem., Oct;54(20):7193-205 (2011)
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients.
Breast Cancer Res., 13(5):R86 (2011)
The challenge and promise of the genomic era.
J. Clin. Oncol., Jan;30(2):203-9 (2012)
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Bioorg. Med. Chem. Lett., Feb;22(4):1569-74 (2012)
Synthesis of 2-[11C]methoxy-3,17Î²-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers.
Steroids., Jul;77(8-9):864-70 (2012)
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
J. Clin. Oncol., Sep;30(25):3051-7 (2012)
ASCO 2012: A Good Year for HER2 Therapy.
Clin. Breast Cancer., Aug;12(4):231 (2012)
Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in cancer.
Steroids., Oct;75(10):715-20 (2010)
Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha).
Appl Radiat Isot., Oct;68(10):1950-8 (2010)
Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer.
Steroids., Dec;75(12):967-73 (2010)
Targeted therapies in early-stage breast cancer: achievements and promises.
Surg. Oncol. Clin. N. Am., Jul;19(3):669-79 (2010)
The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent.
Nucl. Med. Biol., Oct;37(7):763-75 (2010)
The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).
Bioorg. Med. Chem. Lett., Jan;21(1):245-9 (2011)
[11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C.
Bioorg. Med. Chem. Lett., Mar;21(6):1649-53 (2011)
Rethinking the metastatic cascade as a therapeutic target.
Nat Rev Clin Oncol., Jun;8(6):325-32 (2011)
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Bioorg. Med. Chem. Lett., Jun;21(11):3222-6 (2011)
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Invest New Drugs., Dec;27(6):565-70 (2009)
Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
Breast Cancer Res., 11(3):303 (2009)
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Steroids., Nov;74(12):896-905 (2009)
Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.
Breast Cancer Res. Treat., Nov;124(2):327-35 (2010)